Vaccinatie tegen seizoensinfluenza: prioritair de kinderen of andere doelgroepen?

Philippe Beutels, Yannick Vandendijck, Lander Willem, Nele Goeyvaerts, Adriaan Blommaert, Kim Van Kerckhove, Joke Bilcke, Germaine Hanquet, Pieter Neels, Nancy Thiry, Jori Liesenborgs, Niel HensOpenalex Unknown 2013 · DOI · OpenAlex

Abstract: Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) ging na welke aanpak bij griepvaccinatie de hoogste gezondheidswinst per gespendeerde euro zou opleveren. Onderzoekers van de Universiteit Antwerpen en Universiteit Hasselt bestudeerden hiervoor meer dan 5600 mogelijke vaccinatiescenario’s. Een algemene kindervaccinatie zou even kosten-effectief zijn als andere recent ingevoerde kindervaccinaties, op voorwaarde dat de kosten van griepvaccinatie met minstens een kwart dalen. Dit kan door de vaccinatie via de Centra voor Leerlingenbegeleiding of Kind en Gezin te organiseren, en door een prijsdaling van het vaccin. Een toename van de vaccinatiegraad van de volwassenen ouder dan 50 jaar zou het aantal hospitalisaties en overlijdens door griep aanzienlijk verminderen, maar omdat het om een grote groep gaat, zouden de kosten aanzienlijk zijn.

Introduction: The Influenza Policy Dilemma

Influenza remains a significant public health challenge, placing a heavy burden on healthcare systems every winter. Traditionally, vaccination policies have focused on "the sufferers"—the elderly and individuals with underlying health conditions who are at the highest risk of severe complications, hospitalization, and death. However, children are the primary "spreaders" of the virus due to their high infection rates and dense social contact patterns in schools and daycare centers.

The clinical burden of influenza on high-risk individuals remains a primary concern for health policy.

Following the lead of countries like the United Kingdom, Belgium faced a critical policy question: Is it more efficient to vaccinate the spreaders to protect the population indirectly through herd immunity, or to continue focusing resources on the most vulnerable? This report from the Belgian Health Care Knowledge Centre (KCE) provides a comprehensive socio-economic evaluation to answer this question.

Methodology: Modeling 5,600 Scenarios

To capture the complex dynamics of viral transmission and economic impact, researchers from the University of Antwerp and Hasselt University employed a dual-modeling approach:

  • Dynamic Transmission Model (SEIRS): This model accounted for herd immunity by simulating how vaccinating one group (e.g., schoolchildren) reduces the risk for others (e.g., their grandparents). This is crucial for evaluating the indirect benefits of childhood vaccination.
  • Static Models: These were used for specific groups like pregnant women and healthcare workers, where vaccination is unlikely to shift population-wide transmission dynamics significantly.
  • Economic Analysis: The study calculated the Incremental Cost-Effectiveness Ratio (ICER) in Euros per Quality-Adjusted Life Year (QALY), testing 5,667 combinations of age groups, vaccine types (Trivalent Inactivated Vaccine vs. Live Attenuated Influenza Vaccine), and coverage levels.

Key Insights: The Role of Childhood Vaccination

The study found that universal childhood influenza vaccination in Belgium could be a viable strategy, but its cost-effectiveness is highly sensitive to delivery methods. If every child requires a dedicated GP visit for vaccination, the strategy becomes prohibitively expensive.

Universal childhood vaccination is most cost-effective when integrated into existing school-based health programs.

However, if delivery costs are reduced by at least 25%—for example, by organizing vaccination through the Centra voor Leerlingenbegeleiding (CLB) or Kind en Gezin—the ICER drops to levels comparable to other widely accepted vaccines, such as the HPV vaccine. For children, the nasal spray (LAIV) was found to be more cost-effective than the traditional shot (TIV) due to its higher and more stable efficacy across different flu seasons.

Results and Clinical Impact

  • Elderly Priority: Increasing vaccination coverage to 75% for those aged 75 and older remains highly cost-effective (~€24,000/QALY). Despite the potential for herd immunity from children, the elderly still require direct protection because their risk of severe outcomes is so high.
  • Combined Strategy: A strategy combining 80% coverage in children with increased coverage in adults over 50 could prevent approximately 40% of all flu-related hospitalizations and deaths.
  • Pregnant Women: Vaccinating pregnant women is exceptionally cost-effective (<€7,000/QALY) when administered during regular prenatal checkups, as it incurs no additional administration costs.

Conclusion and Limitations

While the model suggests that vaccinating healthy adults (18-49) is the least efficient use of resources, the authors note that this is an economic calculation that ignores societal costs like work absenteeism. Including these indirect costs would likely make all vaccination strategies appear significantly more cost-effective.

Furthermore, a critical gap remains for children under the age of two. This group suffers the highest hospitalization rates, yet the highly effective nasal spray vaccine is not currently indicated for them due to safety concerns. Future policy must balance these economic efficiencies with clinical realities and the logistical challenges of large-scale implementation.

Summary updated

Abstract

Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) ging na welke aanpak bij griepvaccinatie de hoogste gezondheidswinst per gespendeerde euro zou opleveren. Onderzoekers van de Universiteit Antwerpen en Universiteit Hasselt bestudeerden hiervoor meer dan 5600 mogelijke vaccinatiescenario’s. Een algemene kindervaccinatie zou even kosten-effectief zijn als andere recent ingevoerde kindervaccinaties, op voorwaarde dat de kosten van griepvaccinatie met minstens een kwart dalen. Dit kan door de vaccinatie via de Centra voor Leerlingenbegeleiding of Kind en Gezin te organiseren, en door een prijsdaling van het vaccin. Een toename van de vaccinatiegraad van de volwassenen ouder dan 50 jaar zou het aantal hospitalisaties en overlijdens door griep aanzienlijk verminderen, maar omdat het om een grote groep gaat, zouden de kosten aanzienlijk zijn.
BibTeX
@inproceedings{beutels2013vaccinatie,
  author = {Philippe Beutels and Yannick Vandendijck and Lander Willem and Nele Goeyvaerts and Adriaan Blommaert and Kim Van Kerckhove and Joke Bilcke and Germaine Hanquet and Pieter Neels and Nancy Thiry and Jori Liesenborgs and Niel Hens},
  title = {{Vaccinatie tegen seizoensinfluenza: prioritair de kinderen of andere doelgroepen?}},
  booktitle = {Openalex Unknown},
  year = {2013},
  doi = {10.57598/r204as},
}
Figure